The photosynthetic purple nonsulfur bacterium Rhodobacter sphaeroides 2.4.1 can grow aerobically; anaerobically in the presence of external electron acceptors, such as dimethyl sulfoxide (DMSO); photosynthetically in the light; and fermentatively and lithotrophically in the presence or absence of oxygen (52) . This versatility in growth is conferred by the interplay of at least three global gene regulatory systems-the PrrBA two-component system (14, 31) , the AppA/PpsR antirepressor/repressor system (19, 43) , and FnrL (54) . These regulatory systems respond in part to the prevailing cellular redox conditions (37) .
The PrrBA two-component system is comprised of the response regulator PrrA and the histidine kinase/phosphatase PrrB (13, 41) . PrrA is a global regulator that acts as both an activator and a repressor of transcription, involved in the regulation of expression of approximately 25% of the genome (16) . Its gene targets belong to all clusters of orthologous group (COG) functional categories (51; http://www .rhodobacter.org). PrrA and PrrB are homologs of RegA (45) and RegB (40, 49) , respectively, in the related bacterium Rhodobacter capsulatus (11) . Upon phosphorylation by its cognate histidine kinase/phosphatase, PrrB (RegB), PrrA (RegA) dimerizes (30) and binds to DNA using the helix-turn-helix (HTH) motif located at its carboxy-terminal end. Both unphosphorylated PrrA (5, 15a, 44) and unphosphorylated RegA (2, 9, 10, 21, 22) have been reported to bind to DNA in vitro, however, with lower affinity and/or with less specificity than when phosphorylated.
Sequence analysis suggests that PrrA (RegA) comprises two domains. The N-terminal receiver domain, from residues 1 to 130, is a CheY-like domain (35) , common to all bacterial response regulators, whereas the C-terminal effector domain, PrrAC, comprises residue 141 to the C terminus, at residue 184. Residues 160 through 180 form the HTH motif (29) , which is 100% conserved among the protein members of the family (39) . The HTH motif of PrrA belongs to the Escherichia coli Fis (factor for inversion stimulation) family (27) , as predicted by the three-dimensional position-specific scoring matrix method (26) and confirmed by structural studies (29) . Its involvement in DNA binding was shown first in R. capsulatus (9) , and some of its constituent amino acids were identified by mutational analysis in R. sphaeroides (23; J. M. Eraso and S. Kaplan, unpublished data). The PrrA receiver and effector domains are separated by a short linker region that contains a polyproline tract.
Several consensus DNA binding sequences have been previously reported for PrrA (29, 38) and its homologs RegA in R. capsulatus (48, 53) and RegR in Bradyrhizobium japonicum (12) . While there is a measure of agreement in terms of the assignment of two imperfect quasisymmetrical inverted repeats, or half-sites, the DNA sequence per se shows a high degree of degeneracy. By analogy, this conservation of degenerate DNA binding sequence is reminiscent of that found for Fis DNA binding sequences in E. coli (46) .
It has been suggested that the PrrA recognition sequences, or half-sites, in the consensus DNA binding sequence are separated by a spacer region possessing variable length (29, 38) . Our own data, based on the hierarchical clustering analysis of similarly regulated genes, by use of the bioinformatics pro-grams MEME (1) and BioProspector (36) , predicted the existence of two inverted half-sites (1 and 2), encompassing 6 and 5 nucleotides (nt), respectively, separated by a variable spacer region containing anywhere from 0 to 10 nt (38) . The actual PrrA DNA binding sequence reported in this latter study was Y-S-C-G-G-S-gap(0 to 10 nt)-G-W-C-R-M.
In the present study, we studied the specific DNA sequences of the half-sites and the length of the spacer regions between these half-sites for PrrA site 2, in the RSP3361 gene, which is optimal for the anaerobic activation of this gene (16) , and for which we have reported specific binding by PrrA in vitro (15a) . We have tested the contributions of the individual nucleotides present in each of the half-sites, as well as the spacer region length requirement for PrrA binding in vitro, coupled with a determination of these changes on gene expression in vivo. We have found a good correlation between the in vivo and in vitro results and extended the consensus binding site to Y-S-C-G-G-S-gap(0 to 10 nt)-G-W-C-R-M-A, in which the two half-sites contain an equal number of nucleotides (6) . In addition, we determined that the optimal length of the spacer region for this PrrA binding site is 5 nt and provide evidence that phosphorylated PrrA (P-PrrA) binds to consensus sites with an 8-nt spacer region. Thus, we demonstrate that PrrA binds in vitro to flexible DNA sites with variable spacer regions, as previously inferred (29, 38) , and discuss the implications of our findings.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains and plasmids are described in Table 1 ) and were grown as described in the accompanying paper (15a). Plasmids were mobilized, using triparental matings from E. coli DH5␣Phe (14) , into R. sphaeroides strains, as described elsewhere (6) .
DNA manipulations and analysis. Standard protocols or manufacturer's instructions were followed for the isolation of plasmid DNA, as well as for restriction endonuclease, DNA ligase, PCR, and other enzymatic treatments of plasmids and DNA fragments. Enzymes were purchased from New England Biolabs, Inc. (Beverly, MA), Promega Corp. (Madison, WI), United States Biochemical Corp. (Cleveland, OH), Invitrogen (Carlsbad, CA), and Roche (Branchburg, NJ). Plasmid DNA was purified using the Wizard SV miniprep kit from Promega (Madison, WI). DNA fragments were purified using the QIAquick gel extraction kit (Qiagen Inc., Santa Clarita, CA). PfuUltra DNA polymerase was used as the high-fidelity PCR enzyme (Stratagene, Agilent Technologies, La Jolla, CA). Oligonucleotide-directed mutagenesis was performed using PfuUltra DNA polymerase from Stratagene and recombination PCR, as described previously (15) . DNA sequencing was performed as described elsewhere (15a) .
Construction of transcriptional lacZ fusions. pJE4935 harbors the ⌽ (RSP3361-lacZ) transcriptional fusion which contains a 446-bp PCR fragment from the RSP3361 gene (351 bp upstream of the gene and 95 bp within the gene) fused to lacZ in pML5 (16) . The mutant alleles, RSP3361-pbs1 (PrrA binding site) to RSP3361-pbs27, were made using combinatorial PCR (15) and constructed the same as pJE4935, by using PCR fragments containing the respective mutations ( Fig. 1 and Table 1 ). Allele 17 contains two mutations: T to C and A to G* at position 1 in both PrrA half-sites.
In vitro assays. PrrA purification and phosphorylation, radioactive labeling of DNA fragments, DNA binding and competition assays, electrophoretic mobility shift assays (EMSA), and calculation of dissociation and inhibitory constants, K app and K i (18) , respectively, were performed as described in the accompanying paper (15a). pJE5096 is a p-Bend-3 derivative which contains the 16-nt RSP3361 gene PrrA site 2 and adjacent 40 nt on each side as a PCR fragment cloned at its SalI site (15a) . Digestion of pJE5096 with EcoRV yielded a 191-bp fragment containing the wild-type (WT) RSP3361 PrrA site 2 at its center, with adjacent vector sequences. In the case of the mutant alleles, they contained the appropriate mutations in the PrrA site 2. The DNA fragments from all mutant alleles were prepared identically.
The PrrA sites immediately upstream of bchF (the RSP0284 gene, PrrA site B) and pucB (the RSP0314 gene, PrrA site C) were constructed by oligonucleotide hybridization, followed by SalI digestion and subsequent cloning into pBSII. The sizes of the double-stranded DNA fragments were 70 bp and 89 bp, respectively. Oligonucleotides were hybridized by mixing approximately 30 nmol for each of the complementary oligonucleotides and then incubating them in a PTC-100 programmable thermal controller (M. J. Research, Waltham, MA). The hybridization program was designed to decrease the temperature in a stepwise manner from 96 to 40°C (2-degree steps to 80°C, and 5-degree steps from 80 to 40°C). The incubation time was 5 min at each temperature, in 1ϫ KGB buffer: 100 mM potassium glutamate, 25 mM Tris-acetate, 10 mM magnesium acetate, 50 mg/ml bovine serum albumin, and 0.5 mM 2-mercaptoethanol. After hybridization, the KGB concentration was raised to 1.75ϫ, and the double-stranded DNA fragments were cut with SalI, using sites engineered at the ends of the oligonucleotides, and cloned into vector pBSII cut with SalI.
In the case of the PrrA site immediately upstream of ppaA (the RSP0283 gene, PrrA site A), a 240-bp PCR fragment containing this DNA sequence was cloned into pBSII and subsequently digested with EcoRI and HindIII.
␤-Galactosidase assays. R. sphaeroides cultures used for the determination of ␤-galactosidase activity were grown as described previously (14) , and assays were performed as described elsewhere (50) . The data provided are the averages of the results of at least two separate experiments, each performed in duplicate. Standard deviations were always Յ15%. Protein concentrations of cell extracts were determined using the BCA protein assay kit (Pierce, Rockford, IL), with bovine serum albumin as a standard.
Computer programs. Oligo 4.0 (National Biosciences Inc., Plymouth, MN) was used for primer designs. PREDICTOR (University of Sheffield, Department of Chemistry) was used for the calculation of the three-dimensional structure of double-stranded DNA (17) . The VMD (visual molecular dynamics) molecular visualization program was used to display pdb (program database) and other DNA outputs in three dimensions (http://www.ks.uiuc.edu/Research/vmd).
Materials. 5-Bromo-4-chloro-3-indolyl-␤-D-galactoside (X-Gal) was purchased from USB Corporation, Cleveland, OH. o-Nitrophenyl-␤-D-galactopyranoside (ONPG), lithium potassium acetyl phosphate (minimum 85%), spermidine trihydrochloride (minimum 98%), and poly(dA-dT) were purchased from Sigma Chemical Co., St. Louis, MO. GenePure LE agarose was purchased from ISC BioExpress, Kaysville, UT. Iodoacetamide was purchased from Pierce, Rockford, IL. Nonidet P-40 (NP-40) was purchased from Roche, Mannheim, Germany. [␥-
32 P]ATP, at 6,000 Ci/mmol specific activity and 1.7 M concentration, was purchased from Dupont NEN, Boston, MA. All other chemicals used in this work were reagent grade.
RESULTS
Strategy to refine the consensus DNA binding sequence for PrrA. The consensus DNA sequences reported for PrrA binding in R. sphaeroides and its homologs, RegA in R. capsulatus and RegR in B. japonicum, are shown in Fig. 1A . Although they share DNA sequence similarities, overall, they constitute a flexible DNA binding sequence, like the existence of a variable spacer region between the inverted repeats. Of these sequences, our own consensus sequence, which is depicted in line 5 of Fig. 1A , involves two inverted half-sites encompassing 6 and 5 nt, unseparated or separated by a variable spacer region containing anywhere from 1 to 10 nt (38) . When this consensus sequence was used to search for possible PrrA binding sequences in the R. sphaeroides genome, a total of 9,621 putative PrrA binding sequences, roughly one for every 500 bp, were found (data not shown). These potential PrrA binding sequences were located on both strands of the DNA and were distributed proportionally, throughout both the two R. sphaeroides chromosomes (CI and CII) and the five endogenous plasmids. Examination of microarray data (16) comparing gene expression in a PrrA mutant (PrrA2) (13) to that in the WT revealed that a large number of the putative PrrA binding sequences were present in genes which were not regulated by PrrA (16) , placing doubt as to whether these are bona fide PrrA binding sequences.
We recently showed that P-PrrA binds specifically to PrrA site 2 in vitro (15a), which is located in the regulatory region of the RSP3361 gene. The sequence of this PrrA site is shown in Fig. 1B and displays strong dyad symmetry, which is improved by including the 3Ј-most nucleotide in half-site 2 (A), which had not been included in the consensus sequence (38; see below). To determine their individual contributions to PrrA binding, all nucleotides in the PrrA half-sites were mutated to nonconsensus nucleotides, and by deletion or addition of individual nucleotides, the length of the spacer region was changed from 0 to 10 nt and the effects on DNA interactions were investigated. The mutations made by site-directed mu- Half-site 1 Half-site 2
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Contributions of the half-sites to PrrA binding to PrrA site 2 in the RSP3361 gene. Expression of lacZ transcriptional fusions to the RSP3361 gene mutant alleles confirmed that all nucleotides in the half-sites have an effect on RSP3361 gene expression, depending on the substitution. Expression was down 80% to 95%, depending on the nucleotide mutated, compared to the WT, as shown in Fig. 2A (refer to Fig. 1 and Table 1 for allele designations and corresponding mutations). Position 5 in both half-sites, which is devoid of dyad symmetry, was more tolerant to change, depending on the substitution. lacZ fusions to RSP3361-pbs5 (position 5 in half-site 1; G-to-A substitution) and RSP3361-pbs8 (position 5 in half-site 2; Ato-C substitution) showed expression levels similar to those in the WT, whereas the corresponding lacZ fusions to RSP3361-pbs12 (position 5 in half-site 1; G-to-T substitution) and RSP3361-pbs13 (position 5 in half-site 2; A-to-G substitution) were impaired in gene expression to approximately the same levels (80% to 95%).
lacZ fusions to RSP3361-pbs14 (position 1 in half-site 2; A-to-T substitution), and RSP3361-pbs16 (position 1 in halfsite 2; A-to-G substitution) displayed drastically reduced expression levels, approximately 5% and 12%, respectively, compared to the WT, suggesting that the A at position 1 in half-site 2 is likely to be part of the PrrA binding sequence and thereby extends the previously published consensus sequence (38; see below), although the possibility that this nucleotide is part of a "flanking" sequence which affects binding cannot be discounted. These latter two substitutions disrupted the dyad symmetry at position 1 within the half-sites. RSP3361-pbs17 (position 1 in half-sites 1 and 2; T-to-C and A-to-G substitutions, respectively) was constructed to test whether dyad symmetry at this position, rather than DNA sequence per se, was important for RSP3361 gene expression. The transcriptional lacZ fusion to this double mutant allele showed impaired gene expression levels, compared to the WT, indicating that the nature of the nucleotide in position 1, i.e., T (half-site 1)/A (half-site 2), and not just the dyad symmetry, which was also provided by the substituted C (half-site 1)/G (half-site 2) nucleotides, is important for WT gene expression levels.
To determine whether the observed effects on gene expression were due to less-efficient DNA binding per se, we performed EMSA as described in the accompanying paper (15a) and in Materials and Methods, using P-PrrA and linear DNA fragments containing either the WT RSP3361 gene PrrA site 2 or mutant versions containing the mutations described above. While a P-PrrA-DNA complex was formed when using a WT DNA fragment and P-PrrA at the concentrations determined previously (15a) (Fig. 2B, lanes 1 and 2) , protein-DNA complex formation was impaired in the presence of most of the mutant DNA fragments. Only when DNA fragments corresponding to RSP3361-pbs5 (position 5 in half-site 1; G-to-A) (Fig. 2B, lanes 11 and 12) and RSP3361-pbs8 (position 5 in half-site 2; A-to-C) (Fig. 2B, lanes 17 and 18) were used did P-PrrA-DNA complex formation compare favorably to that formed by the WT. These results were in agreement with those observed in vivo, with the lacZ transcriptional fusions. When RSP3361-pbs1 (position 1 in half-site 1; T-to-A) (Fig. 2B, lanes  3 and 4) and RSP3361-pbs15 (position 1 in half-site 1; T-to-C) (Fig. 2B, lanes 31 and 32) were used, an approximately 75% decrease in binding was observed, compared to the WT. These two alleles showed an approximately 80% decrease in lacZ expression, compared to the WT. Thus, these results from both in vitro and in situ experiments correlated remarkably well, indicating that decreased RSP3361 gene expression is most likely dictated by the reduced P-PrrA binding affinity to the mutant DNA sequences.
Competition with DNA fragments containing mutations in the PrrA half-sites. The decrease in P-PrrA binding affinity to the mutant DNA sequences correlated with the ability of these same mutant DNA fragments to serve as specific competitors for P-PrrA binding, as expected. These data are shown in Fig.  3 and in Table S1 in the supplemental material. As previously reported, a linear DNA fragment containing the WT RSP3361 gene PrrA site 2 (RSP3361-WT) competed for P-PrrA binding to the equivalent labeled WT DNA fragment (15a). The calculated K i (inhibitory constant) was 2.5 ϫ 10 Ϫ12 M and represents the concentration of the competitor DNA required to displace 50% of the labeled DNA from a P-PrrA-WT DNA complex. This concentration of competitor DNA constituted an ϳ8-fold molar excess over the labeled WT DNA used in the reaction (Fig. 3, top panel) .
When using linear mutant DNA fragments, we calculated the K i 's of those fragments corresponding to RSP3361-pbs1 (position 1 in half-site 1; T-to-A substitution) (K i ϭ 3.4 ϫ 10 Ϫ12 M), RSP3361-pbs5 (position 5 in half-site 1; G-to-A substitution) (K i ϭ 4.3 ϫ 10 Ϫ12 M), and RSP3361-pbs8 (position 5 in half-site 2; A-to-C substitution) (K i ϭ 2.9 ϫ 10 Ϫ12 M). The latter had the lowest inhibitory constant, as expected, likely due to the fact that its affinity for P-PrrA was similar to that displayed by the WT DNA fragment ( Fig. 3 ; see Table S1 in the supplemental material). The K i values for RSP3361-pbs7 (position 6 in half-site 2, G-to-A substitution), RSP3361-pbs14 (position 1 in half-site 2, A-to-T substitution), and RSP3361-pbs16 (position 1 in half-site 2, A-to-G substitution) could not be quantitated, since DNA fragments corresponding to these alleles failed to displace 50% of the bound labeled WT DNA from P-PrrA-WT DNA complexes. Thus, the results of the competition experiments are in good agreement with those obtained for P-PrrA DNA binding in vitro and the results of lacZ transcriptional fusions. The data reveal that all nucleo- Table S1 in the supplemental material. Assuming that the extra nucleotide added to half-site 2 contacts PrrA, these results also extend the length of the consensus half-site 2 within PrrA site 2 in RSP3361 gene from 5 to 6 nucleotides and, thus, suggest that P-PrrA binds to this DNA sequence using two quasisymmetrical half-sites of equal length. Effect of spacer region length in PrrA site 2 in the RSP3361 gene. Expression of lacZ transcriptional fusions to RSP3361 gene mutant alleles containing mutations affecting the length of the spacer region, as described in Fig. 1, Table 1 , and Fig.  4A , compared to the WT, revealed that a spacer region length of 5 nt is optimal for RSP3361 gene expression. When the expression of transcriptional lacZ fusions containing mutant spacer regions with different lengths was compared to that of the WT, lacZ expression was found to be decreased from 50%, in the case of RSP3361-pbs25, containing an 8-nt spacer, to 80%, in the case of RSP3361-pbs19, which contains only a 1-nt spacer region, a G (refer to Fig. 1C ), compared to the WT, as shown in Fig. 4A . In the cases where there was no spacer region or where the spacer region lengths encompassed either 1, 2, 4, 7, 9, or 10 nt, these reduced lacZ expression levels obtained for the mutant alleles were similar in either the WT cells or the PrrA2 mutant, as shown previously when the entire PrrA site 2 was deleted (16) . The exception was RSP3361-pbs25, containing an 8-nt spacer region, for which expression in the PrrA2 mutant was approximately 20% that in the WT. As in the case of mutations affecting the DNA half-sites, to investigate whether the alterations in spacer region length affected the ability of PrrA to bind to DNA, we performed EMSA. While a P-PrrA-DNA complex was formed when using a WT DNA fragment (Fig. 4B, lanes 1 and 2) , complex formation proved to be intolerant to change in spacer region length. As an internal control, a DNA fragment corresponding to RSP3361-pbs1, which had been previously shown to bind P-PrrA, although with less affinity than the WT (Fig. 2B, lanes  3 and 4) , was included in the experiments. These results were in good agreement with those observed in vivo with the lacZ transcriptional fusions.
Competition experiments were performed using DNA fragments corresponding to two of the spacer region mutants, since all remaining mutant DNA fragments showed similar P-PrrA binding impairments. Linear DNA fragments containing either 4 or 6 nucleotides in the spacer region were compared to the WT for their ability to serve as specific competitors for P-PrrA binding to WT DNA sequences. The DNA fragments corresponding to RSP3361-pbs22 (G-C-C-A [SP ϭ 4, where SP is the number of nucleotides in the spacer region between halfsites 1 and 2]) and RSP3361-pbs23 (G-C-C-A-T-C [SP ϭ 6]), for which we show competition kinetics in Fig. 5 , were not good competitors, compared to the WT. Their calculated inhibitory constants, 1.4 ϫ 10 Ϫ11 M for RSP3361-pbs22 and 1.3 ϫ 10
Ϫ11
M for RSP3361-pbs23, constituted an approximately 40-fold molar excess (see Table S1 in the supplemental material) with respect to the concentration of labeled WT DNA, and were approximately 5-fold larger than that calculated for the WT RSP3361-WT (K i ϭ 2.5 ϫ 10 Ϫ12 M) ( Fig. 5 ; see Table S1 in the supplemental material). When taken together, these results suggest that a spacer region containing 5 nucleotides is optimal for P-PrrA binding to PrrA site 2 of the RSP3361 gene.
Identification of additional DNA sequences to which PrrA binds in vitro. To ascertain whether presumptive PrrA DNA binding sequences can accommodate a spacer region with different lengths, as hypothesized previously (29, 38) , several DNA sequences present in genes regulated, either positively or negatively, by PrrA, as determined from microarray data (16), were chosen for study in vitro. Three of these DNA sequences, PrrA site A (Fig. 6A) , located immediately upstream of ppaA (RSP0283 gene); PrrA site B (Fig. 6B) , immediately upstream of bchF (RSP0284 gene); and PrrA site C (Fig. 6D) , present in the regulatory region of pucB (RSP0314 gene) (Fig. 6E) , were shown to specifically bind P-PrrA in vitro. PrrA sites A and B are separated by 117 nt and are located in the intergenic region between ppaA (RSP0283 gene) and bchF (RSP0284 gene), shown in Ϫ7 M for PrrA site C. These K app 's are similar to, although slightly higher than, that previously calculated for P-PrrA binding to PrrA site 2 in the RSP3361 gene, which was 1.3 ϫ 10 Ϫ7 M (15a). Thus, we have shown that P-PrrA binds in vitro to DNA sites with at least two different spacer region lengths.
In Fig. 7 , we have aligned the DNA sequences shown to bind P-PrrA in vitro, both in this study and in the accompanying paper (15a). We have incorporated 8 nucleotides on each side of these DNA sequences, so as to be able to compare the flanking DNA sequences. Nucleotides at positions 3, 4, and 5 in half-site 1 and at positions 2, 4, and 6 in half-site 2 are conserved. Assuming that PrrA makes contacts with these nucleotides and that it binds to DNA as a dimer (29) , this suggests that the contacts made by the two PrrA monomers are different. In three of these PrrA binding sequences, the length of the spacer region is 5 nucleotides, which, coincidentally, was the most abundant spacer length found in the study which unveiled the consensus PrrA binding sequence used here (38) . This means that the two half-sites are separated by the longitudinal distance corresponding to 5 nucleotides or are approximately a half-turn of the DNA helix in rotational shift, using the helical axis as a reference and assuming a straight conformation for the DNA. In the case of the 8-nt spacer region, these parameters would be different; the longitudinal distance would be longer, determined by the three additional nucleotides present, and the orientation of the half-sites would be approximately three-fourths of a turn of the DNA helix.
DISCUSSION
In this study, we have investigated the DNA sequence in each of the half-sites, as well as the length of the spacer regions between these half-sites, involved in the binding of the response regulator PrrA to PrrA site 2 of the RSP3361 gene (15a, 16) . We show here that the P-PrrA DNA binding sequence is composed at least of two nearly symmetrical inverted half-sites, each encompassing 6 nucleotides. Mutation of every nucleotide within these half-sites led to decreased P-PrrA Ϫ12 M for RSP3361-WT (circles) and 1.4 ϫ 10 Ϫ11 M for both RSP3361-pbs22 (squares) and RSP3361-pbs24 (diamonds) correspond to 50% displacement of P-PrrA, or 0.5 fractional saturation. The concentrations of competitor DNA are the same as those shown in Fig. 3 . The EMSA results from which these data were derived are not shown.
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on February 21, 2013 by PENN STATE UNIV http://jb.asm.org/ binding affinity, the magnitude of which was dependent on the substitution, as shown by direct DNA binding and the results of competition experiments. The decrease in P-PrrA binding affinity to the mutant DNA sequences correlated with in vivo results obtained by assaying for gene expression using transcriptional ⌽(RSP3361-lacZ) fusions containing the same mutations and the WT sequence. Whether the 6 nucleotides in these half-sites constitute "real" contact points for P-PrrA has not been determined in this study. The presence of a 5-nt spacer region in PrrA site 2 of the RSP3361 gene is optimal for P-PrrA binding in vitro, as shown by the decrease in binding affinity to synthetic spacer sequences containing 0 to 10 nucleotides, in comparison to the WT spacer region, which contains 5 nucleotides. These results were confirmed by competition experiments using DNA fragments containing spacer regions with either a deletion or addition of 1 nucleotide. The expression of ⌽(RSP3361-lacZ) transcriptional fusions containing the synthetic spacer regions, ranging in length from 0 to 10 nucleotides, was reduced in all cases, compared to the WT.
PrrA site A, upstream of ppaA, and PrrA site C, upstream of pucB, also contain spacer regions with 5 nucleotides and bound P-PrrA in vitro. In addition, we have shown P-PrrA binding to PrrA site B, in front of bchF, which contains 8 nucleotides in its spacer region. These exact same DNA sequences, mapping to genes that are positively regulated by PrrA, are unique since 
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Upstream of pucB http://jb.asm.org/ they were not found elsewhere in the genome. Thus, these findings validate the binding assay for P-PrrA reported both here and elsewhere (15a) and confirm predictions made previously (29, 38) . Importantly, the strength of the binding of P-PrrA is independent of the length of the spacer region when different binding sequences are considered. The length of the spacer region should determine the longitudinal difference, or distance, as well as the rotational shift with respect to the DNA helical axis, of the PrrA half-sites. Assuming an approximate value of 34.3 degrees/base pair (20) and a straight conformation for the DNA helix, the half-sites 1 and 2 in the DNA sequences which bind PrrA reported here should be either 171.5 or 274.4 degrees apart, relative to the helical axis, when containing spacer regions with 5 or 8 nucleotides, respectively. Thus, provided that P-PrrA binds to DNA as a dimer (30) , the dimer must accommodate variable longitudinal differences and rotational shifts between the half-sites and must therefore bind to DNA in a flexible manner. Even in terms of a suboptimal number of nucleotides in the spacer region, some lengths might be favored over others, as shown here for RSP3361-pbs25. The synthetic spacer region in this allele encompasses 8 nucleotides, instead of 5 like the WT allele, and it showed the highest expression in vivo, compared to the other spacing alleles, although it was still reduced compared to the WT.
The optimal length of the spacer region for an individual PrrA site might therefore depend upon several factors. It might be determined in relation to the DNA sequence of the corresponding half-sites, since the orientation of the half-sites with respect to the DNA helix would depend on the number of nucleotides separating them (4), and/or in relation to additional contextual parameters, like the composition of the DNA sequences flanking the half-sites. Furthermore, the DNA sequence of the nucleotides in the spacer region, which was not tested here, might constitute a determinant of PrrA binding. Finally, an additional requirement could be the presence of specific metabolites, protein factors, or DNA topology (15a) .
Alignment of the DNA sequences reported here, which correspond to genes for which PrrA is acting as a transcriptional activator, allowed us to determine the conserved nucleotide pairs in these P-PrrA binding sequences, although it has not been shown that these residues contact P-PrrA directly. We found the DNA sequence of the half-sites to be different, depending on the PrrA site; nucleotides at positions 3, 4, and 5 were conserved in half-site 1 and nucleotides at positions 2, 4, and 6 in half-site 2, suggesting that the PrrA monomers bind asymmetrically, as reported for the Lac repressor (24) . No other additional similarities between PrrA DNA binding sequences were found. The dyad symmetry between the inverted half-sites varied-from the strongest, in PrrA site 2 (RSP3361 gene), which encompassed 5 nucleotides, to that in PrrA site B (bchF), where only 2 nucleotides were symmetrical. The AϩT richness of the spacer region varied from 100%, in PrrA site C (pucB), to 37.5%, in PrrA site B (bchF), whereas that of the flanking DNA sequences varied between 12.5% for PrrA site C The heterogeneity in terms of DNA sequence within the PrrA sites reported here agrees with the earlier predictions for a consensus DNA binding site (12, 29, 38, 48, 53) , and it strengthens our previous argument involving a role for DNA topology in PrrA-DNA recognition (15a). Therefore, we propose that both a "direct readout" (or digital) mechanism, in which the DNA sequence per se is the main determinant for PrrA binding, as shown by the mutational analysis conducted here, and an "indirect readout" (or analog) mechanism, in which the DNA sequence determines a specific DNA conformation which increases PrrA DNA binding affinity, as suggested for other transcriptional regulators (8, 42) , might serve to dictate the binding specificity for PrrA to its target sites. Thus, defining a general PrrA consensus DNA binding sequence in terms of only a direct readout mechanism might not be very straightforward, since the topology of those DNA sequences might in part determine their PrrA binding affinity.
This degeneracy in PrrA DNA binding sequences might account for the high percentage of gene targets, about 25% of the genome, found for this global response regulator, although this is a high estimate, since indirect regulation must account for a portion of this percentage (16) . In addition, since different DNA sequences show different P-PrrA binding affinities, as shown here and elsewhere (15a), the cellular levels of P-PrrA, as dictated by the redox state of the electron transport chain (37) , are likely to determine a hierarchy in gene expression, as defined by the affinity of PrrA for the different DNA binding sequences.
In conclusion, we have investigated, both here and in another report (15a), some of the parameters determining PPrrA binding to the PrrA site 2 in the RSP3361 gene, and we have, in addition, shown P-PrrA binding to additional sites, confirming that the spacer region in the DNA binding sequence can accommodate variable lengths. It remains to be investigated whether the spacer region in PrrA binding DNA sequences permits further flexibility, in terms of its length, whether the DNA sequence of this region per se has an influence on PrrA binding, and even whether flanking DNA sequences might have possible effects. To this purpose, chromatin immunoprecipitation, which has recently yielded new target DNA sequences for the repressor PpsR (3), should prove valuable for identifying additional targets for P-PrrA binding. Work is in progress to test for PrrA binding in vitro to operator sites, where this protein would act as a repressor provided it binds to DNA directly to repress gene expression, and to investigate whether the defining characteristics for "activator" sites are similar to those for "repressor" sites.
